Focal Segmental Glomerulosclerosis Market: Epidemiology, Therapies, Companies, DelveInsight | Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, Pfizer, Chinook Therapeutics, Inc., Genentech, Complexa, Imara, ZyVersa, Boehringer Ingelhe

Focal Segmental Glomerulosclerosis therapies, such as LEQVIO (Inclisiran), Olpasiran (AMG 890), and others, are expected to boost the Focal Segmental Glomerulosclerosis Market in the upcoming years.

DelveInsight has launched a new report on "Focal Segmental Glomerulosclerosis - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Focal Segmental Glomerulosclerosis, historical and forecasted epidemiology as well as the Focal Segmental Glomerulosclerosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Focal Segmental Glomerulosclerosis market report @ https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Focal Segmental Glomerulosclerosis Market Report:

The Focal Segmental Glomerulosclerosis (FSGS) market is expected to witness steady growth from 2023 to 2034, driven by the anticipated approval of promising therapies.
In May 2025, the FDA officially accepted Travere Therapeutics' supplemental New Drug Application (sNDA) for traditional approval of sparsentan (brand name FILSPARI) for FSGS, supported by strong data from the Phase 3 DUPLEX and Phase 2 DUET trials
According to DelveInsight's analysis, the United States accounts for the largest share of diagnosed FSGS cases in the 7MM, representing approximately 46.96% of the total. Japan follows, contributing around 14.83% of diagnosed cases in 2022.
Our research suggests that FSGS affects males more frequently than females across the 7MM, potentially due to hormonal, genetic, or environmental factors.
In 2022, the FSGS market within the 7MM primarily comprised treatments such as statins, Ezetimibe/Bempedoic Acid combinations, and PCSK9 inhibitors, collectively generating nearly USD 23 million in revenue.
In 2022, among the EU4 and the UK, Germany reported the highest number of diagnosed prevalent cases of Focal Segmental Glomerulosclerosis (FSGS), with around 5 million cases, followed by France and Italy. Conversely, Spain recorded the lowest number of diagnosed prevalent cases in this group.
DelveInsight's 2022 analysis of gender-specific FSGS prevalence across the 7MM revealed that approximately 40% of the diagnosed cases occurred in males, while females accounted for about 60%.
Key Focal Segmental Glomerulosclerosis companies such as Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, Pfizer, Chinook Therapeutics, Inc., Genentech, Complexa, Imara, ZyVersa, Boehringer Ingelheim, Eli Lilly and Company, and others are evaluating new drugs for Focal Segmental Glomerulosclerosis to improve the treatment landscape.
Promising Focal Segmental Glomerulosclerosis therapies include LEQVIO (Inclisiran), Olpasiran (AMG 890), and others.

Focal Segmental Glomerulosclerosis Overview

Focal Segmental Glomerulosclerosis (FSGS) is a kidney disorder characterized by scarring (sclerosis) that occurs in specific sections (focal) of the glomeruli-the tiny filtering units within the kidneys. These glomeruli play a crucial role in producing urine by filtering out waste and excess fluid from the bloodstream.
Common symptoms of FSGS include proteinuria (excessive protein in the urine), edema (swelling in areas such as the eyes, hands, feet, and abdomen, often leading to sudden weight gain), low levels of albumin in the blood, high cholesterol, elevated blood pressure, and in some cases, an increased risk of blood clots.

Focal Segmental Glomerulosclerosis Market Outlook

Focal Segmental Glomerulosclerosis (FSGS) is a complex condition linked to various disorders such as coronary artery disease (CAD), peripheral artery disease (PAD), and cerebrovascular disease, all commonly associated with atherosclerosis. The development of FSGS is influenced by genetic factors, lifestyle choices, and existing health conditions. Treatment strategies differ based on disease severity, with the primary goal of managing and slowing its progression. Initial treatment often focuses on lifestyle modifications, including stress reduction, regular physical activity, dietary changes, and smoking cessation. These measures can enhance the effectiveness of medications and help reduce cardiovascular risk factors by improving patient outcomes.

As the FSGS treatment landscape advances, the emergence of Olpasiran, currently in Phase III clinical trials, offers promising potential as a targeted therapy. Its anticipated launch is expected to significantly drive growth in the FSGS market across the 7MM, with the market value projected to approach USD 837 million by 2034.

In 2022, the FSGS market in the 7MM was valued at around USD 734 million, with steady growth expected throughout the forecast period. Among these regions, Japan led the market, accounting for nearly 46% of the total drug sales for FSGS in 2022.

Discover how the Focal Segmental Glomerulosclerosis market is rising in the coming years @ https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Focal Segmental Glomerulosclerosis Emerging Drugs
Olpasiran (AMG 890): Amgen Inc.
Focal Segmental Glomerulosclerosis Marketed Drugs

LEQVIO (Inclisiran): Novartis Pharmaceuticals Corporation

Scope of the Focal Segmental Glomerulosclerosis Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Focal Segmental Glomerulosclerosis Companies: Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, Pfizer, Chinook Therapeutics, Inc., Genentech, Complexa, Imara, ZyVersa, Boehringer Ingelheim, Eli Lilly and Company, and others
Focal Segmental Glomerulosclerosis Therapies: LEQVIO (Inclisiran), Olpasiran (AMG 890), and others.
Focal Segmental Glomerulosclerosis Therapeutic Assessment: Focal Segmental Glomerulosclerosis current marketed and Focal Segmental Glomerulosclerosis emerging therapies
Focal Segmental Glomerulosclerosis Market Dynamics: Focal Segmental Glomerulosclerosis market drivers and Focal Segmental Glomerulosclerosis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Focal Segmental Glomerulosclerosis Unmet Needs, KOL's views, Analyst's views, Focal Segmental Glomerulosclerosis Market Access and Reimbursement

To know what's more in our Focal Segmental Glomerulosclerosis report, visit https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Focal Segmental Glomerulosclerosis Market Report:
The Focal Segmental Glomerulosclerosis market report covers a descriptive overview and comprehensive insight of the Focal Segmental Glomerulosclerosis Epidemiology and Focal Segmental Glomerulosclerosis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Focal Segmental Glomerulosclerosis market report provides insights into the current and emerging therapies.
The Focal Segmental Glomerulosclerosis market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Focal Segmental Glomerulosclerosis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Focal Segmental Glomerulosclerosis market.

Got queries? Click here to know more about the Focal Segmental Glomerulosclerosis market Landscape https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Focal Segmental Glomerulosclerosis Patient Share (%) Overview at a Glance
5. Focal Segmental Glomerulosclerosis Market Overview at a Glance
6. Focal Segmental Glomerulosclerosis Disease Background and Overview
7. Focal Segmental Glomerulosclerosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Focal Segmental Glomerulosclerosis
9. Focal Segmental Glomerulosclerosis Current Treatment and Medical Practices
10. Unmet Needs
11. Focal Segmental Glomerulosclerosis Emerging Therapies
12. Focal Segmental Glomerulosclerosis Market Outlook
13. Country-Wise Focal Segmental Glomerulosclerosis Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Focal Segmental Glomerulosclerosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Focal Segmental Glomerulosclerosis Market Outlook 2034 https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Focal Segmental Glomerulosclerosis Pipeline Insights, DelveInsight

"Focal Segmental Glomerulosclerosis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Focal Segmental Glomerulosclerosis market. A detailed picture of the Focal Segmental Glomerulosclerosis pipeline landscape is provided, which includes the disease overview and Focal Segmental Glomerulosclerosis treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.